-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

959 Pre-Clinical Evaluation of AZD5492, a Novel CD8-Guided T Cell Engager, for B-Non Hodgkin Lymphoma Indications

Program: Oral and Poster Abstracts
Type: Oral
Session: 605. Molecular Pharmacology and Drug Resistance: Lymphoid Neoplasms: Novel Therapeutic Approaches in Lymphoma
Hematology Disease Topics & Pathways:
Research, Translational Research, Drug development, Bispecific Antibody Therapy, Treatment Considerations, Biological therapies
Monday, December 9, 2024: 5:30 PM

Rachel Lawrence1*, Corinne Cayatte, PhD2*, Macarena Izuzquiza Fernandez3*, Scott Rata4*, Thomas Ciucci2*, Wen Lin2*, Abigail Lara2*, Nazli Jafarzadeh2*, Taylor Foreman2*, Sterling Payne5*, Harini Shandilya5*, Nisha Sambamurthy6*, Haibin Luo7*, Richard Stebbings1*, Simon Dovedi8*, Gullu Gorgun9*, Anthony Mato10*, Saso Cemerski2*, Mark Cobbold11* and Anas Younes10

1Safety Sciences, AstraZeneca, Early Oncology R&D, Cambridge, United Kingdom
2Immune Engagers, AstraZeneca, Early Oncology R&D, Gaithersburg, MD
3Clinical, AstraZeneca, Hematology R&D, Barcelona, Spain
4Translational DMPK, AstraZeneca, Early Oncology R&D, Waltham, MA
5Biologics Engineering, AstraZeneca, Early Oncology R&D, Gaithersburg, MD
6Translational Medicine, AstraZeneca, Hematology R&D, South San Francisco, CA
7Biopharmaceutical Development, BioPharmaceutical R&D, Gaithersburg, MD
8Immune Engagers, AstraZeneca, Early Oncology R&D, Cambridge, United Kingdom
9AstraZeneca Hematology R&D, Waltham, MA
10AstraZeneca Hematology R&D, New York, NY
11Immune Engagers, AstraZeneca, Early Oncology R&D, Waltham, MA

Introduction

Non-Hodgkin lymphomas (NHL) include diverse neoplasms of the lymphoid compartment, with the majority originating from the B-cell lineage. Bispecific CD20xCD3 T cell engagers (TCEs), both monovalent and bivalent, have shown promising rates of ORRs and CRs in the clinic leading to several FDA approvals for the treatment of R/R DLBCL and FL. However, these treatments are still associated with significant toxicities, including CRS and ICANS, limiting their therapeutic window and potential for clinical combinations.

Methods

We engineered a first-in-class CD8-guided TCE, AZD5492, for B-NHL malignancies. AZD5492 is an asymmetric, trispecific monoclonal IgG1 antibody which harbors two Fab binding domains to CD20, one VHH binding domain to TCR, one VHH binding domain to CD8 co-receptor. AZD5492 binding, cytolytic activity, and efficacy were extensively interrogated in vitro and in vivo, in murine models and in non-human primates (NHP).

Results

The VHH domains of AZD5492 allow preferential engagement of CD8+ T cells through CD8/TCR binding, leading to the formation of an artificial immunological synapse with CD20+ target cells, T-cell activation and target B cell killing. Compared to conventional CD20xCD3 TCEs, which equally engage and activate CD4+ and CD8+ T cells, AZD5492 drives potent B cell killing through preferential engagement of CD8+ T cells, with reduced CD4+ T cell activation and associated cytokine production. In NSG humanized mice engrafted subcutaneously or intravenously with B cell tumors, AZD5492 conferred potent and dose-dependent anti-tumor efficacy. When compared to conventional bivalent CD20xCD3 TCEs, comparable anti-tumor efficacy was achieved with significantly less systemic cytokine production. Importantly, repeated dosing of AZD5492 was also evaluated in cynomolgus monkey for up to 1 month and induced a marked and prolonged decrease in CD19+ and CD20+ B cells in the blood and in tissues (lymph nodes, spleen, and bone marrow). Transient cytokine increases were observed post-first dose of AZD5492 but was not associated with notable toxicity. Overall, AZD5492 was well tolerated in cynomolgus monkeys and a NOAEL was established at 3 mg/kg.

Conclusions

AZD5492 represents a first-in-class T cell engager for the treatment of B cell lymphomas. Compared to conventional CD3-based T cell engagers, AZD5492 anti-tumor activity in murine models was associated with low cytokine release and this favorable safety profile was recapitulated in NHP. AZD5492 has therefore the potential to significantly improve therapeutic index. AZD5492 IND has been approved by the FDA and a FIH study in patients with R/R NHL and CLL is ongoing.

Disclosures: No relevant conflicts of interest to declare.

*signifies non-member of ASH